I hope that I'm wrong. Many more patients can possibly be saved with more widespread use of this treatment. Of course, the FDA needs to modernize their own approval processes to deal with such personalized treatments. It's my understanding that my lab-expanded lymphocytes needed to be individually approved by the FDA.
I do know that my specific trial at NIH was sponsored by Lion Biotechnologies as part of that company acquiring a license to reproduce the laboratory processing for the TIL ACT.
I do know that my specific trial at NIH was sponsored by Lion Biotechnologies as part of that company acquiring a license to reproduce the laboratory processing for the TIL ACT.